JP2006508965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508965A5 JP2006508965A5 JP2004551895A JP2004551895A JP2006508965A5 JP 2006508965 A5 JP2006508965 A5 JP 2006508965A5 JP 2004551895 A JP2004551895 A JP 2004551895A JP 2004551895 A JP2004551895 A JP 2004551895A JP 2006508965 A5 JP2006508965 A5 JP 2006508965A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocyclyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 49
- 229910005965 SO 2 Inorganic materials 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 42
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 40
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 22
- -1 aryl-C 1 -C 4 alkyl- Chemical group 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 241000124008 Mammalia Species 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims 6
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 5
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 5
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 5
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 108060006698 EGF receptor Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 230000008728 vascular permeability Effects 0.000 claims 3
- 102000044591 ErbB-4 Receptor Human genes 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 2
- 108010090091 TIE-2 Receptor Proteins 0.000 claims 2
- 102000012753 TIE-2 Receptor Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 102000009929 raf Kinases Human genes 0.000 claims 2
- 108010077182 raf Kinases Proteins 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 108091008606 PDGF receptors Proteins 0.000 claims 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42422302P | 2002-11-06 | 2002-11-06 | |
| PCT/US2003/035588 WO2004043379A2 (en) | 2002-11-06 | 2003-11-06 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508965A JP2006508965A (ja) | 2006-03-16 |
| JP2006508965A5 true JP2006508965A5 (OSRAM) | 2006-12-21 |
Family
ID=32312770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004551895A Withdrawn JP2006508965A (ja) | 2002-11-06 | 2003-11-06 | 化学物質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060241149A1 (OSRAM) |
| EP (1) | EP1581514A2 (OSRAM) |
| JP (1) | JP2006508965A (OSRAM) |
| AR (1) | AR041992A1 (OSRAM) |
| AU (1) | AU2003290661A1 (OSRAM) |
| TW (1) | TW200418466A (OSRAM) |
| WO (1) | WO2004043379A2 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| EP1713484A2 (en) * | 2004-01-23 | 2006-10-25 | Amgen Inc. | Compounds and methods of use |
| PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| GB0421525D0 (en) * | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| HUE047422T2 (hu) * | 2005-12-23 | 2020-04-28 | Ariad Pharma Inc | Biciklusos heteroaril vegyületek |
| GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| GB0605120D0 (en) * | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| EA200870514A1 (ru) | 2006-05-08 | 2009-04-28 | Ариад Фармасьютикалз, Инк. | Ацетиленовые гетероарильные соединения |
| US20090324581A1 (en) * | 2006-05-09 | 2009-12-31 | Daiichi Sankyo Company Limited | Heteroarylamide lower carboxylic acid derivative |
| US8217045B2 (en) * | 2007-04-17 | 2012-07-10 | Novartis Ag | Organic compounds |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| CA2815506C (en) | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| CN104496940B (zh) * | 2014-01-06 | 2017-03-15 | 广东东阳光药业有限公司 | 一种制备bcr‑abl抑制剂中间体的方法 |
| CN110483482A (zh) * | 2018-05-15 | 2019-11-22 | 北京诺诚健华医药科技有限公司 | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
| WO2022146755A1 (en) * | 2020-12-29 | 2022-07-07 | Merck Sharp & Dohme Corp. | Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses |
| EP4353309A4 (en) * | 2021-05-26 | 2025-05-07 | Sumitomo Pharma Co., Ltd. | PHENYLUREA DERIVATIVE |
| CN116265452A (zh) * | 2021-12-17 | 2023-06-20 | 中国科学院上海药物研究所 | 含氮杂环化合物、其制备方法及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1506962B1 (en) * | 2000-10-20 | 2008-07-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic heterocycles |
-
2003
- 2003-11-04 TW TW092130770A patent/TW200418466A/zh unknown
- 2003-11-04 AR ARP030104037A patent/AR041992A1/es unknown
- 2003-11-06 US US10/533,832 patent/US20060241149A1/en not_active Abandoned
- 2003-11-06 AU AU2003290661A patent/AU2003290661A1/en not_active Abandoned
- 2003-11-06 JP JP2004551895A patent/JP2006508965A/ja not_active Withdrawn
- 2003-11-06 WO PCT/US2003/035588 patent/WO2004043379A2/en not_active Ceased
- 2003-11-06 EP EP03783243A patent/EP1581514A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508965A5 (OSRAM) | ||
| JP2008523099A5 (OSRAM) | ||
| JP2015511638A5 (OSRAM) | ||
| JPWO2021168193A5 (OSRAM) | ||
| JPWO2020260252A5 (OSRAM) | ||
| JP2013512903A5 (OSRAM) | ||
| RU2003117476A (ru) | Аминотиазолы и их применение в качестве антагонистов рецептора аденозина | |
| JP2017528487A5 (OSRAM) | ||
| JP2019510796A5 (OSRAM) | ||
| JP2007505933A5 (OSRAM) | ||
| JP2008514732A5 (OSRAM) | ||
| JP2020516621A5 (OSRAM) | ||
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| JP2012529486A5 (OSRAM) | ||
| JP2006523193A5 (OSRAM) | ||
| CN109475539B (zh) | 帕金森氏病的治疗 | |
| JP2015501833A5 (OSRAM) | ||
| JP2011529474A (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2008506714A5 (OSRAM) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2007520452A5 (OSRAM) | ||
| JP2003525234A (ja) | カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| JP2003525244A (ja) | 抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| JP2006523192A5 (OSRAM) | ||
| JP2003525235A (ja) | 抗腫瘍ヌクレオシド誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 |